WaveTec secures investment

Article

In a new round of financing, investor, Burril & Company, has given WaveTec $16.5 million to commercialize its ORA System.

In a new round of financing, Burrill & Company, has given WaveTec $16.5million to commercalize its ORA system.

Tom Frinzi, WaveTec president and CEO, said, "The participation of a new lead investor further validates the scientific and clinical potential of the ORA System, This new capital enables us to further expand our commercial efforts as well as continue product refinement. We’re confident of our leadership in this space and of our ability to help surgeons provide superior refractive cataract outcomes.”

According to the company, the system enables surgeons to optomize results in cataract patients due to enhanced quality wavefront image. It features precision lenses, offering better accuracy and improving outcomes for patients.

Live display of the eye is available in full-field view for quality image captures, meaning surgeons can identify and diagnose measurements. Intraoperative astigmatic correction is guided by a system-aligned, on-demand reticle. This provides axial guidance for toric lens and limbal relaxing incision placement.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.